Navigation Links
Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
Date:3/25/2013

EXTON, Pa., March 25, 2013 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs and the world leader in the in-vitro classification of drugs according to the Biopharmaceutics Classification System (BCS), announces that it has registered with the United States Food and Drug Administration (FDA) as a generic drug facility under the Generic Drug User Fee Amendments of 2012 (GDUFA). As required by GDUFA, the company self-identified as a BCS, bioequivalence (BE), and bioavailability (BA) testing facility and is now on the FDA's list of registered facilities. In addition, to take advantage of the emerging markets of Central and South America, Absorption Systems' Panama operation will be registered with the FDA as a generic drug facility under GDUFA in the second half of 2013. Central and South America will benefit tremendously from the regional presence of an established leader in the field of BCS, BE and BA.  

GDUFA, which applies to generic drugs, is part of the 2012 renewal of the Prescription Drug User Fee Act (PDUFA), originally enacted in 1992 and renewed every five years thereafter. Both authorize the FDA to collect user fees from drug sponsors at the time of submission of a marketing application: new drug application (NDA) for a proprietary, branded drug or abbreviated new drug application (ANDA) for a generic drug. In exchange, a time limit is imposed on the agency's review of each application. PDUFA is credited with greatly improving the efficiency of new drug reviews by the FDA; the average review time for priority drugs has dropped from 24 months in 1992 (pre-PDUFA) to 13 months in 2012. GDUFA is expected to help reduce the current backlog of generic drug reviews, which is due to the increase in the number of generic drug applications, their growing complexity, and the need to inspect the growing number of generic drug facilities located overseas.

Absorption Systems' activities related to GDUFA involve classification of drug active ingredients according to the BCS. Part of the FDA drug approval pathway since 2000, the BCS classifies drugs according to the solubility and permeability of their active pharmaceutical ingredients (APIs). Absorption Systems is the world leader in the measurement of drug permeability for BCS classification. Drugs that meet the criteria for BCS Class I (high permeability and solubility) are eligible for a biowaiver, which simplifies the process of drug development.

Patrick Dentinger, President and CEO of Absorption Systems, commented that "The world is gradually realizing what a unique and reliable approach to accelerating product approval the BCS is. Whereas GDUFA is expected to reduce the backlog of generic reviews, the BCS eliminates unnecessary human testing and dramatically reduces both the time and cost of product approval."

Collectively, these steps will benefit BCS adopters in the US and around the globe. The interest and growth in BCS applications have regulatory agencies around the world taking notice. With that in mind, Absorption Systems has expanded its support for the burgeoning pharmaceutical industry in Latin America by establishing its facility in Panama, in anticipation of increased demand for BCS-related studies.          

About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit www.absorption.com.  

Chris Bode
Absorption Systems
1-610-280-1451
cbode@absorption.com
www.absorption.com  


'/>"/>
SOURCE Absorption Systems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Delcath Systems, Inc. Secures $20 Million Credit Facility
3. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
6. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
7. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
8. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
9. Veeva Systems Announces Dramatic Growth in Europe
10. PLC Systems Reports First Quarter 2012 Results
11. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, announced ... been deployed to improve patient care, reduce turnaround times and to ... Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral CCG ...
(Date:2/4/2016)... , Feb. 4, 2016  The Senior Care ... Government Reform Committee Chairman Jason Chaffetz ... holding today,s hearing , "Developments in the ... increases and growing questions about abusive pharmacy benefit ... (R-UT) and Ranking Member Elijah Cummings (D-MD) ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, ... it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the ... oral health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
(Date:2/5/2016)... ... 2016 , ... California Mobile Kitchens , a company ... latest mobile kitchen model, featuring customizable stainless steel interiors and a new, 26-foot ... use anywhere in the U.S. Many of their units can be seen at ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
Breaking Medicine News(10 mins):